Close
Almac
Achema middle east

Chinese Drug Development Fund Gets $500mn Boost In Hong Kong

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.
- Advertisement -

The Hong Kong government announced plans to add $500 million to the Chinese Medicine Development Fund beginning with this fiscal year during a budget speech in order to support the commissioning of large-scale training, research, and publicity projects on strategic themes and to advance more capacity-building programmes for the sector, including making preparations for Hong Kong’s first Chinese medicine hospital, which is expected to commence its operations in 2025, and thereby strengthen the Chinese medicine role when it comes to the primary healthcare system.

Several varied practitioners as well as organizations involved in the Chinese medicine industry have benefited from the rollout of more than ten funding schemes since the Chinese Medicine Development Fund’s formal launch in 2019.

It is well to be noted that at the end of the previous year, the government unveiled the Primary Healthcare Blueprint, which outlines several crucial reform initiatives for enhancing Hong Kong’s primary healthcare services and adopts prevention-oriented, community-based, family-centered, as well as early detection and intervention strategies. The goal of the Blueprint is to improve the general public’s health by developing a sustainable healthcare system and offering comprehensive and coordinated healthcare services.

Apparently, as introduced in the Blueprint, the government will launch the Chronic Disease Co-Care Pilot Scheme and enhance measures to the Elderly Health Care Voucher Scheme. The government is most likely to announce the details in the third quarter of 2023 and reserve enough financial resources for the schemes.

Latest stories

Related stories

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »